Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC22 combined with ART in HIV-1 infection
NCT05330143Phase 2Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jun 2022
- Primary completion
- May 2024
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Ascletis Pharma Inc.. Started Jun 2022; status: completed.
02
Drugs
envafolimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05330143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05330143.